Biogen is hungry for deals—but the less risk, the better Roche drops solid tumor option, intensifying the squeeze on SQZ Astellas notches another protein degrader pact with $21M upfront for PeptiDream Stoke’s Dravet syndrome data spooks investors with high rates of adverse events Humanigen mulls bankruptcy after reverse merger falls through Heron lays off 25% of employees and renegotiates vendor contracts to save money New mRNA vaccine for malaria uses cancer immunotherapy adjuvant to improve efficacy To prevent cancer metastasis, prevent protein migration, new study suggests Fierce Biotech Fundraising Tracker '23: Crescendo raises $32M to fund Keytruda expansion arm; Renibus reels in $47M | 